Representative immunohistochemical staining for MYH9 in NSCLC.

<p>A: MYH9 was strongly expressed in the membrane of tumor cells in adenocarcinoma. B: MYH9 was strongly expressed in the membrane and cytoplasm of tumor cells in squamous cell carcinoma. (original magnification: A, B ×400).</p

Immunohistochemical screening of the Ku-Lu-6 antibody with AMeX-fixed LCN1-cis (A) and LCN1 (B) cells.

<p>Membranous staining was observed in LCN1-cis cells, but not in LCN1 cells. (original magnification: A, B ×400).</p

Relationships between MYH9 Expression and Clinicopathological parameters.

<p>* See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0121460#pone.0121460.t001" target="_blank">Table 1</a> for explanation of abbreviations and note on asterisk.</p><p>Relationships between MYH9 Expression and Clinicopathological parameters.</p

Characteristics of the Patients.

<p>AD = adenocarcinoma; NS = never smoker; p-TNM = pathological TNM; S = smoker</p><p>SQ = squamous cell carcinoma</p><p>*Each case was reassigned to a pathological stage on the basis of the IASLC Lung Cancer Staging Project (seventh edition).</p><p>Characteristics of the Patients.</p

Immunoprecipitation with KU-Lu-6 antibody.

<p>Lane 1: molecular weight marker, lane 2: LC-2/ad-cis lysate combined with KU-Lu-6 antibody, lane 3: LC-2/ad-cis lysate combined with protein L, lane 4: KU-Lu-6 antibody combined with protein L, lane 5: LC-2/ad-cis lysate. Lanes 3 and 4 are negative controls, and specific immunoprecipitated product with KU-Lu-6 antibody was detected in lane 2 (arrow).</p

Cumulative survival of patients with NSCLC according to MYH9 expression estimated by the Kaplan-Meier method.

<p>(A) for all patients; (B) for patients with adenocarcinoma; (C) for patients with squamous cell carcinoma, treating all other causes of death and lost to follow-up as censored cases. MYH9 expression was significantly correlated with poorer survival in resected NSCLCs.</p

Antibody absorption test for MYH9.

<p>KU-LU-6 antibody supernatant was pre-absorbed with none (A), 0.12 ug (B), 0.24 ug (C), and 0.48 ug (D) of synthetic MYH9 proteins. Each absorbed antibody was immunostained with formalin-fixed LC2/ad-cis cells. The stainability of KU-Lu-6 antibody was gradually reduced depending on the concentration of MYH9 protein.</p

Relationships between nestin expression and clinicopathological parameters.

<p>Relationships between nestin expression and clinicopathological parameters.</p

Cumulative survival of patients with NSCLC according to nestin expression estimated by the Kaplan-Meier method.

<p>Panel (A) and (B) shows disease-free survival (DFS) and overall survival (OS), respectively. Nestin expression is significantly associated with poorer survival in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy, whereas there was no association between DFS and nestin expression.</p

Representative cases of each EMT phenotype according to expression of E-cadherin and vimentin.

<p>The cases are divided into the following 4 phenotypes; complete type, incomplete type1 (hybrid type), incomplete type2 (null type), and wild type (Lo, loss; Pr, preserve; P, positive; N, negative. original magnification, ×200).</p